114 related articles for article (PubMed ID: 27813536)
1. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
[No Abstract] [Full Text] [Related]
2. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Khoury JD; Ai D; Tang Z; Tang G; Jorgensen JL; Medeiros LJ; Hu S
Leukemia; 2015 Nov; 29(11):2263-6. PubMed ID: 25931274
[No Abstract] [Full Text] [Related]
3. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
4. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
[No Abstract] [Full Text] [Related]
5. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Gong Z; Zheng L; Tang Z; Chen Z; Wang W; Bai S; Tang G; Medeiros LJ; Hu S
Ann Hematol; 2017 Mar; 96(3):501-504. PubMed ID: 27915425
[No Abstract] [Full Text] [Related]
6. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
Zámecníkova A; Al Bahar S; Ramesh P
Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB; Bendit I; Boquimpani C; De Souza CA; Miranda EC; Zalcberg I; Larripa I; Nardinelli L; Silveira RA; Fogliatto L; Spector N; Funke V; Pasquini R; Hungria V; Chiattone CS; Clementino N; Conchon M; Moiraghi EB; Lopez JL; Pavlovsky C; Pavlovsky MA; Cervera EE; Meillon LA; Simões B; Hamerschlak N; Bozzano AH; Mayta E; Cortes J; Bengió RM;
Cancer Invest; 2015; 33(9):451-8. PubMed ID: 26288116
[TBL] [Abstract][Full Text] [Related]
8. Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Chen Z; Wang W; Rich A; Tang G; Hu S
Am J Hematol; 2015 Aug; 90(8):E146-8. PubMed ID: 25960187
[No Abstract] [Full Text] [Related]
9. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
10. Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
Breccia M; Stagno F; Gozzini A; Abruzzese E; Latagliata R; Rossi AR; Sorà F; Porrini R; Vigneri P; Trawinska M; Montefusco E; Sica S; Specchia G; Santini V; Alimena G
Am J Hematol; 2011 Jun; 86(6):523-5. PubMed ID: 21594891
[No Abstract] [Full Text] [Related]
11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
12. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
13. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
Takahashi N
Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
[No Abstract] [Full Text] [Related]
14. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
15. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
Haematologica; 2017 Dec; 102(12):e486-e489. PubMed ID: 28860340
[No Abstract] [Full Text] [Related]
16. Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.
Assal A; Dong B; Khan H; Medavarapu R; Shastri A; Pradhan K; Friedman E; Mantzaris I; Janakiram M; Battini R; Kornblum N; Yu Y; Verma A; Braunschweig I; Derman O
Leuk Lymphoma; 2016 Oct; 57(10):2452-5. PubMed ID: 26886689
[No Abstract] [Full Text] [Related]
17. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
18. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Hwang YY; Tse E; So JC; Wan TS; Kwong YL
Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
[No Abstract] [Full Text] [Related]
19. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
[TBL] [Abstract][Full Text] [Related]
20. Trisomy 5 in Ph+ chronic myeloid leukemia in association with megakaryocytosis.
Ansell SM; Rapoport BL; Coccia-Portugal MA; Stevens K; Bester CJ; Falkson G
Cancer Genet Cytogenet; 1991 Feb; 51(2):273-5. PubMed ID: 1993312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
